NCT04237623 2026-04-16
GM-CSF With Post-Transplant Cyclophosphamide
Northside Hospital, Inc.
Phase 2 Recruiting
Clinical Trials
13 trialsNCT05544968 2026-04-03
Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies
Medical College of Wisconsin
Phase 1 Recruiting
NCT06450041 2026-03-23
NANT 2021-01 Phase II STING (Sequential Temozolomide, Irinotecan, NK Cells and GD2 mAb) Trial
New Approaches to Neuroblastoma Therapy Consortium
Phase 2 Recruiting
NCT04936529 2026-03-13
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT04144023 2026-03-05
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
Mayo Clinic
Phase 1 Recruiting
NCT03363373 2026-02-19
Naxitamab for High-Risk Neuroblastoma Patients With Primary Refractory Disease or Incomplete Response to Salvage Treatment in Bone and/or Bone Marrow
Y-mAbs Therapeutics
Phase 2 Recruiting
NCT06528496 2026-02-10
N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma
Memorial Sloan Kettering Cancer Center
Phase 2 Recruiting
NCT06626516 2025-11-28
Tebentafusp-tebn With LDT in Metastatic UM
Thomas Jefferson University
Phase 1/2 Recruiting
NCT06799026 2025-09-02
A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma
Beth Israel Deaconess Medical Center
Phase 1 Recruiting
NCT06651853 2025-07-23
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
The First Affiliated Hospital of Xiamen University
Phase 2 Recruiting
NCT06013618 2025-06-17
Clinical Analysis of Naxitamab (hu3F8) in the Treatment of Pediatric High Risk or Refractory/ Relapsed Neuroblastoma
Sun Yat-sen University
Phase 2 Recruiting
NCT06472739 2024-06-25
The Effect of GM-CSF to Preventing Oral Mucositis for Patients With Nasopharyngeal Carcinoma Receiving Radiotherapy
Sun Yat-sen University
Phase 2 Recruiting
NCT05817214 2024-04-19
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer
Zhongnan Hospital
Phase 2 Recruiting